Edit Startup: Neurowyzr

You do not have permission to edit this page, for the following reason:

The action you have requested is limited to users in the group: Users.

Welcome! You're creating or editing a startup page.

If you haven't, we suggest reading our general editing principles first. Also note our position on AI-generated content.

How to use the template

Fill out the form, then add the page content below.

Form

None of the form's fields are strictly mandatory, so skip them if you are uncertain of the values.

Page Content

We strongly suggest using the Visual Editor. To do this:

Saving the page after filling up the form
Click on the "Edit" link on the top right of the newly created page.

Before moving further, please read the following notes on the page template:

Where information is unavailable or unsubstantial, delete sections as necessary
Add sections as necessary
If you substantially adapt from Wikipedia (which is okay), include {{From_Wikipedia}} at the bottom of the page

Logo:	Upload file
Status:
Website (include https://):
Vertical(s):
Technology Readiness Level:	Research (TRL 1-3) Development (TRL 4-6) Deployment (TRL 7-8) Fully Commercialised (TRL 9) Unknown/Not Applicable
Latest Funding:
Founding Year:
Headquarters:
Active In (other countries):
Spun off from:

Page Content
{{PAGENAME}} is a Singapore-based healthtech startup specializing in enhancing brain health and developing state-of-the-art technologies to mitigate early brain decline. ==Technology== The startup's first product is an online gamified digital neuroscience assessment that significantly reduces the time and dollar burden of traditional cognitive testing<ref name=":0">{{Cite web |last=Staff |first=TechNode Global |date=2023-08-24 |title=Singapore's Neurowyzr raises additional $2.1M in seed funding co-led by Jungle Ventures and Peak XV’s Surge |url=https://technode.global/2023/08/24/singapores-neurowyzr-raises-additional-2-1m-in-seed-funding-co-led-by-jungle-ventures-and-peak-xvs-surge/ |access-date=2025-12-05 |website=TNGlobal |language=en-US}}</ref>. This product has been notified with the respective regulatory bodies in Singapore, India, Malaysia, Indonesia, Thailand, Australia, Vietnam, United Kingdom and the United States. ==Traction== Neurowyer's digital neuroscience assessment has been used across many of Singapore's health screening centers, general practitioners (GP) clinics, community care, and specialist centers, including Parkway Shenton, SATA Commhealth, Farrer Park Hospital, MHC Medical Centre (Amara), and O’Joy<ref name=":0" />. It has also been piloted in one of India's largest private hospital chains<ref name=":0" />. ==Funding== In 2023, Neurowyzer raised a seed round lead by Jungle Ventures and Peak XV’s Surge<ref name=":0" />.{{Startup/Funding history}} == References == {{Reflist}}

Summary:

Cancel